Maria Pia Abruzzese

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9304314/publications.pdf

Version: 2024-02-01

8 papers

405 citations

8 h-index 8 g-index

8 all docs 8 docs citations

8 times ranked 814 citing authors

#	Article	IF	CITATIONS
1	Activation of liver X receptor upâ€regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms. FASEB Journal, 2019, 33, 9489-9504.	0.5	19
2	The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors. Cell Death and Disease, 2019, 10, 324.	6.3	11
3	Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis. Oncolmmunology, 2017, 6, e1279372.	4.6	100
4	p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. Oncolmmunology, 2017, 6, e1264564.	4.6	29
5	Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. Journal of Hematology and Oncology, 2016, 9, 134.	17.0	72
6	Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer. Current Medicinal Chemistry, 2016, 23, 2618-2636.	2.4	42
7	Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. BMC Cancer, 2015, 15, 17.	2.6	54
8	The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. Oncotarget, 2015, 6, 23609-23630.	1.8	78